Skip to main content

Table 3 Trachea and lung pathology after challenge.

From: Alternating 3 different influenza vaccines for swine in Europe for a broader antibody response and protection

Vaccine group

% macroscopic pneumonia ± SD (number of pigs with lesions)

Microscopic lesion score ± SD (number of pigs with lesions)

Cardiac lung

Trachea

IPAW

PBLC

Neutro’s

Mock-vaccinated challenge control

5.2 ± 5.5 (5)

0.3 ± 0.5 (2)

1.0 ± 0.6 (5)

0.3 ± 0.5 (2)

0.3 ± 0.5 (2)

3xTIV

2.0 ± 2.5 (5)

1.6 ± 0.9 (4)

1.6 ± 0.6 (6)

1.3 ± 0.8 (5)

0.8 ± 0.4 (5)

3xBIV

1.8 ± 4.1 (2)

0.4 ± 0.7 (2)

1.3 ± 1.2 (4)

0.7 ± 1.2 (2)

0.5 ± 0.6 (3)

3xMOV

3.2 ± 4.7 (4)

0.3 ± 0.8 (1)

1.1 ± 1.0 (4)

0.3 ± 0.8 (1)

0.3 ± 0.5 (2)

TIV–BIV–MOV

0.6 ± 1.2 (2)

0.0

0.8 ± 1.0 (3)

0.0

0.0

BIV–TIV–MOV

0.1 ± 0.2 (1)

0.0

0.7 ± 0.8 (3)

0.2 ± 0.4 (1)

0.0

  1. TIV: Respiporc® FLU3; BIV: GRIPORK®; MOV: Respiporc® FLUpan H1N1.
  2. Macroscopic pneumonia: the percentage of the surface affected with pneumonia was estimated visually for each lobe and the total percentage for the entire lung was calculated, based on weighted proportions of each lobe to the total volume. Microscopic lung lesion scores are based on the severity of 3 parameters: (1) IPAW: epithelial damage in intrapulmonary airways (0–3), (2) PBLC: peribronchiolar lymphocytic cuffing (0–3), (3) Neutro’s: neutrophil exudation in bronchioles and alveoli (0–2); Microscopic tracheal lesion scores are based on the severity of epithelial damage (0–2).